VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Details

Request a copyRequest a copy
Serval ID
serval:BIB_E123EA0B584E
Type
Article: article from journal or magazin.
Publication sub-type
Editorial
Collection
Publications
Institution
UNIL/CHUV
Title
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Journal
Annals of Oncology
Author(s)
Soo R., Han J-Y., Dimopoulou G., Cho B.C., Yeo C.M., Nadal E., Carcereny E., de Castro J., Sala M.A., Bernabe R., Coate L., Provencio M., Campelo R. Garcia, Cuffe S., Hashemi S., Früh M., Ruepp B., Roschitzki-Voser H., Stahel R., Peters S.
ISSN
0923-7534
Publication state
Published
Issued date
07/2021
Volume
32
Number
7
Pages
942-944
Language
english
Keywords
Oncology, Hematology
OAI-PMH
oai:serval.unil.ch:BIB_E123EA0B584E
DOI
10.1016/j.annonc.2021.04.010
Web of science
000761582600001
Open Access
Yes
Create date
18/03/2022 18:10
Last modification date
11/11/2022 6:39
Usage data